Veru Inc Dossier
Qualitative Analysis
Business overview
Veru Inc. (NASDAQ: VERU) is a late clinical-stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). The company's drug development pipeline is anchored by two late-stage novel small molecules: enobosarm, an oral selective androgen receptor modulator (SARM) being developed to enhance fat loss while preserving lean muscle mass in conjunction with GLP-1 receptor agonists, and sabizabulin, an oral targeted cytoskeleton disruptor being evaluated across multiple oncology and ARDS indications. Veru previously marketed the FC2 Internal Condom, but completed the sale of its FC2 Female Condom business on December 30, 2024, to Clear Future, Inc. for $18 million in cash, transitioning the company into a pure-play biopharmaceutical developer.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Developing enobosarm, an oral selective androgen receptor modulator (SARM), as a combination therapy with GLP-1 receptor agonists (specifically semaglutide) to target selective fat loss while preserving lean muscle mass, physical function, and bone mineral density in older patients with obesity.
Expected impact: Addresses the critical unmet need of muscle loss and weight loss plateaus associated with GLP-1 therapies, positioning Veru in the rapidly expanding multi-billion dollar obesity market.
Developing sabizabulin, an oral microtubule disruptor with broad anti-inflammatory properties, for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity C-reactive protein (hsCRP) in patients with stable coronary artery disease.
Expected impact: Expands the pipeline into cardiometabolic and inflammatory diseases, targeting high-risk cardiovascular patients.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Novo Nordisk supplies Wegovy (semaglutide for injection) at no charge for Veru's Phase 2b PLATEAU clinical trial. Veru retains full global development and commercialization rights to enobosarm, while Novo Nordisk holds a right of first negotiation for future combinations of enobosarm with its GLP-1 products.
Terms: Wegovy is supplied at no cost to Veru for the duration of the trial; Novo Nordisk receives a right of first negotiation for future combination products.